Surufatinib Plus Immunotherapy Shows Promise as Maintenance Therapy for Aggressive Lung Cancer
A phase 2a trial found that surufatinib combined with PD-1/PD-L1 inhibitors as first-line maintenance therapy yielded a median progression-free survival ...
